You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 1080 Using site-specific chemical conjugation to generate superior half-life extended or PD-1-targeted formats of a potent IL-18 variant resistant to IL-18 binding protein

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immune-Stimulants and Immune Modulators
1080 Using site-specific chemical conjugation to generate superior half-life extended or PD-1-targeted formats of a potent IL-18 variant resistant to IL-18 binding protein
Free

Authors

Citation

Carralot J, Delon C, Sanchez RA, et al
1080 Using site-specific chemical conjugation to generate superior half-life extended or PD-1-targeted formats of a potent IL-18 variant resistant to IL-18 binding protein
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.1080

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.